Table 1.
MIR alterations across pancreatic cancer stages.
| Stage I (N = 7) | Stage II (N = 94) | Stage III (N = 6) | Stage IV (IV = 2) |
|---|---|---|---|
| MIR27A | MIR27A | ||
| MIR31 | MIR31 | MIR27A | |
| MIR93 | MIR93 | MIR31 | |
| MIR96 | MIR96 | MIR93 | |
| MIR122 | MIR122 | MIR96 | |
| MIR130B | MIR130B | ||
| MIR133A1 | MIR130B | ||
| MIR203A | MIR203A | MIR133A1 | |
| MIR210 | MIR210 | MIR203A | |
| MIR330 | MIR330 | MIR210 | MIR210 |
| MIR339 | MIR339 | MIR330 | |
| MIR425 | MIR425 | ||
| MIR429 | MIR429 | ||
| MIR522 | MIR429 | MIR429 | |
| MIR590 | MIR522 | ||
| MIR664A | MIR590 | ||
| MIR1208 | MIR664A | ||
| MIR3620 | MIR3620 | MIR1208 | MIR1208 |
The cBioPortal tool is a publicly curated database and enables the addition of several different tracks, including a tumor staging track. The tumor stage track was utilized to identify the stages of the 109 patients who participated in the UTSW study. The table reports the number of patients per stage and which MIRs exhibited alteration, defined as either MIR amplification or deletion, for that particular stage. Stage, patient population per stage, and the MIRs altered in each patient sampling are indicated.